Advertisement

Systemic Lupus Erythematosus

  • Michelle Petri
  • Rachel Abuav
  • Dimitrios Boumpas
  • Fiona Goldblatt
  • David Isenberg
  • Grant J. Anhalt
  • Victoria P. Werth
  • R. John Looney
Chapter

Abstract

Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease, associated with autoantibody production and evidence for immune complex deposition among the many aspects of its pathophysiology. SLE occurs most commonly in women during their reproductive years. The disease is approximately nine times more common among women than men. Virtually any organ can be affected by SLE. However, constitutional symptoms, mucocutaneous features, mus-culoskeletal involvement, and renal and central nervous system disease are the most common manifestations. Many aspects of SLE appear to be triggered by classic inflammatory mechanisms, accompanied by elevated acute phase reactants, and responsive to immunosuppres-sive therapies. Other aspects, such as those associated with antiphospholipid antibodies (aPL), are associated with hypercoagulability. Although inflammation contributes to these aspects as well, the approach to the treatment of aPL-mediated disease manifestations is usually centered on anticoagulation. Autoantibodies can occur in the absence of clinical features of SLE, but strong evidence implicates certain autoantibodies in the mediation of tissue damage in the kidney and other organs. Genetics plays a significant role in SLE, but the disease is clearly polygenic, with multiple genetic risk factors contributing incrementally to the overall genetic risk. Environmental risk factors are also critical. Established environmental risk factors for the disease include hormones, ultraviolet light, the exposure to certain medications, and possibly dietary exposures and infectious agents.

Keywords

Systemic Lupus Erythematosus Systemic Lupus Erythematosus Patient Lupus Nephritis Mycophenolate Mofetil Lupus Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: Effects on disease activity. J Rheumatol 2000; 27(7):1681–1685PubMedGoogle Scholar
  2. ACR ad hoc committee on neuropsychiatric lupus. The American College of Rheumatology nomenclature and case definitions for neuropsychi-atric lupus syndrome. Arthritis Rheum 1999; 42:599–608Google Scholar
  3. Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology 2006; 45:1144–1147PubMedCrossRefGoogle Scholar
  4. Advisory Committee on Immunization Practices (ACIP). Recommendations for the Prevention of Herpes Zoster Morbidity and Mortality Weekly Report Recommendations and Reports June 6, 2008/Vol. 57/ RR-5(www.cdc.gov/mmwr)
  5. Aguilera P, Mascaró JM Jr, Martinez A, et al Cutaneous gamma/delta T-cell lymphoma: A histopathologic mimicker of lupus erythemato-susprofundus (lupus panniculitis). J Am AcadDermatol 2007; 56:643–647CrossRefGoogle Scholar
  6. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythemato-sus. Neurology 2001; 57(3):496–500PubMedCrossRefGoogle Scholar
  7. Akkasilpa S, Goldman D, Magder LS, Petri M. Number of fibromyalgia tender points is associated with health status in patients with systemic lupus erythematosus. J Rheumatol 2005; 32(1):48–50PubMedGoogle Scholar
  8. Appel G, Contreras G, MA D, et al Mycophenolate Mofetil versus Cyclophosphamide as Lupus Nephritis Induction Treatment. J Am Soc Nephrol 2009; 20(5):1103–12PubMedCrossRefGoogle Scholar
  9. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus ery-thematosus: An open-label study. Arthritis Rheum 2004; 50(10):3161–3169PubMedCrossRefGoogle Scholar
  10. Austin H, Klippel J, Balow J, et al Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. NEJM 1986; 314:614–619PubMedCrossRefGoogle Scholar
  11. Baca V, Lavalle C, Garcia R, et al Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999; 26:432–439PubMedGoogle Scholar
  12. Barr S, Zonana-Nacach A, Magder L, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42:2682–2688PubMedCrossRefGoogle Scholar
  13. Bertsias G, Ioannidis JP, Boletis J, et al Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67(2):195–205PubMedCrossRefGoogle Scholar
  14. Bijl M, Kallenberg CG. Ultraviolet light and cutaneous lupus. Lupus 2006; 15(11):724–727PubMedCrossRefGoogle Scholar
  15. Boddaert J, Huong D, Zahir A, Wechsler B, Godeau P, Piette J. Late-onset systemic lupus erythematosus: A personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine 2004; 83:348–359PubMedCrossRefGoogle Scholar
  16. Bombardier C, Gladman DD, Urowitz M, Caron D, Chang CH, the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992; 35:630–640PubMedCrossRefGoogle Scholar
  17. Boumpas D, Yamada H, Patronas N, Scott D, Klippel J, Balow J. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81:975–984PubMedCrossRefGoogle Scholar
  18. Boumpas DT, Sidiropoulos P, Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? Nat Clin Pract Rheumatol 2005; 1(1):22–30PubMedCrossRefGoogle Scholar
  19. Brooks SM, Werk EE, Ackerman SJ, et al Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972; 286:1125–1128PubMedCrossRefGoogle Scholar
  20. Bruce I, Gladmann D, Urowitz M. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient non-adherence. Arthritis Care Res 2000; 13:406–408PubMedCrossRefGoogle Scholar
  21. Buyon J, Petri MA, Kim M Y, et al The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005; 142:953–962PubMedCrossRefGoogle Scholar
  22. Callen JP. Cutaneous lupus erythematosus: A personal approach to management. Australas J Dermatol 2006; 47(1):13–27PubMedCrossRefGoogle Scholar
  23. Calvo-Alen J, Alarcon GS, Burgard SL, et al Systemic lupus erythema-tosus: Predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: Multivariate analyses and identification of risk factors. J Rheumatol 1996; 23:469–475PubMedGoogle Scholar
  24. Carrie F, Roblot P, Bouquet S, et al: Rifampin-induced nonresponsive-ness of giant cell arteritis to prednisone treatment. Arch Intern Med 1994; 154:1521–1524PubMedCrossRefGoogle Scholar
  25. Cervera R, Khamashta M, Font J, et al Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine 1993; 72:113–124PubMedCrossRefGoogle Scholar
  26. Chambers S, Charman S, Rahman A, Isenberg D. Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Ann Rheum Dis 2007; 66:1173–1177PubMedCrossRefGoogle Scholar
  27. Chan MT. Owen P. Dunphy J, et al Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 2008; 35(1):77–83PubMedGoogle Scholar
  28. Chan TM, Li FK, Tang CS, et al Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343 (16):1156–1162PubMedCrossRefGoogle Scholar
  29. Christopher-Stine L, Siedner M, Lin H, Haas M, Parekh H, Petri M, et al Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 2007; 34:332–335PubMedGoogle Scholar
  30. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345(12):925–926PubMedCrossRefGoogle Scholar
  31. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350(10):971–980PubMedCrossRefGoogle Scholar
  32. Costallat L, Coimbra A. Systemic lupus erythematosus: Clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol 1994; 12:603–607PubMedGoogle Scholar
  33. Cusack C, Danby C, Fallon JC, et al Photo protective behaviour and sunscreen use: Impact on vitamin D levels in cutaneous lupus erythe-matosus. Photodermatol Photoimmunol Photomed 2008; 24:260–267PubMedCrossRefGoogle Scholar
  34. Damian-Abrego G, Cabiedes J, Cabral A. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus 2008; 17:300–304PubMedCrossRefGoogle Scholar
  35. Danowski A, Magder L, Petri M. Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J Rheumatol 2006; 33(1):57–60PubMedGoogle Scholar
  36. Domenech I, Aydintug O, Cervera R, et al Systemic lupus erythemato-sus in 50 year olds. Postgrad med J 1992; 68:440–444PubMedCrossRefGoogle Scholar
  37. Elkayam O, Paran D, Caspi D, et al Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34:147–153PubMedCrossRefGoogle Scholar
  38. Elkayam O, Paran D, Burke M, et al Pneumococcal vaccination of patients with systemic lupus erythematosus: Effects on generation of autoantibodies. Autoimmunity 2005; 38:493–496PubMedCrossRefGoogle Scholar
  39. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al Aspirin for primary thrombosis prevention in the antiphospho-lipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56(7):2382–2391PubMedCrossRefGoogle Scholar
  40. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythema-tosus. Arthritis Rheum 2001; 44(10):2331–2337PubMedCrossRefGoogle Scholar
  41. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: Diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006; 33:1563–1569PubMedGoogle Scholar
  42. Feldman R, Salmon D, Saurat JH. The association of the two antimalari-alschloroquine and quinacrine for treatment-resistantchronic and sub-acutecutaneous lupus erythematosus. Dermatology 1994;186:425–427CrossRefGoogle Scholar
  43. Fernandez M, Calvo-Alen J, Bertoli A, et al Systemic lupus erythemato-sus in a multiethnic US cohort (LUMINA L II): Relationship between vascular events and the use of hormone replacement therapy in post-menopausal women. J Clin Rheumatol 2007; 13:261–265PubMedCrossRefGoogle Scholar
  44. rent headache in patients with systemic lupus erythematosus: A case control study. Lupus 1999; 8(2):151–156PubMedCrossRefGoogle Scholar
  45. Fessler B. Infectious diseases in systemic lupus erythematosus:risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 2002; 16:281–291PubMedCrossRefGoogle Scholar
  46. Fessler BJ, Alarcon GS, McGwin G, Jr., Roseman J, Bastian HM, Friedman AW, et al Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52(5):1473–1480PubMedCrossRefGoogle Scholar
  47. Font J, Pallares L, Cervera R, et al Systemic lupus erythematosus in the elderly: Clinical and immunological charracteristics. Ann Rheum Dis 1991; 50:702–705PubMedCrossRefGoogle Scholar
  48. Foote R, Kimbrough S, Stevens J. Lupus myositis. Muscle Nerve 1982; 5:65–68PubMedCrossRefGoogle Scholar
  49. Formiga F, Moga I, Pac M, Mitjavila F, Rivera A, Pujol R. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. Lupus 1999; 8:462–465PubMedCrossRefGoogle Scholar
  50. Fusconi M, Vannini A, Dall'aglio AC, Pappas G, Bianchi FB, Zauli D. Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis. Rheumatol Int 2007; 28(1):47–49PubMedCrossRefGoogle Scholar
  51. Ganczarczyk L, Urowitz MB, Gladman DD. Latent lupus. J Rheumatol 1989; 16:475–478PubMedGoogle Scholar
  52. Geraminejad P, Stone MS, Sontheimer RD. Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus. Lupus 2004; 13:473–477PubMedCrossRefGoogle Scholar
  53. Gilland WR, Tsokos GC. Prophylactic use of antibiotics and immunisations in patients with SLE. Ann Rheum Dis 2002 Mar; 61(3):191–192CrossRefGoogle Scholar
  54. Gilliam JN, Cheatum DE, Hurd ER, Stastny P Ziff M. Immuno globulin in clinically uninvolved skin in systemic lupus erythematosus: Association with renal disease. J clin invest 1974; 53(5):1434–1440PubMedCrossRefGoogle Scholar
  55. Ginsburg KS, Liang MH, Newcomer L, et al Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117:997–1002PubMedCrossRefGoogle Scholar
  56. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353(21):2219–2228PubMedCrossRefGoogle Scholar
  57. Gladman D, Hussain F, Ibanez D, Urowitz M. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002; 11:234–239PubMedCrossRefGoogle Scholar
  58. Glas-Vos Jd, Krediet R, Weening J, Arisz L. Treatment of proliferative lupus nephritis with methylprednisolone pulse therapy and oral aza-thioprine. Neth J Med 1995; 46:4–14PubMedCrossRefGoogle Scholar
  59. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases. J Rheumatol 1994; 21(2):246–251PubMedGoogle Scholar
  60. Gorbache AV, Gasparian AV, Gurova KV, et al Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation. Eur J Immunol 2007; 37:2257–2267CrossRefGoogle Scholar
  61. Graninger, Smolen JS. Incomplete lupus erythematosus: Results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) 2001; 40:89–94Google Scholar
  62. Grootscholten C, Ligtenberg G, Hagen E, et al Azathioprine/methyl-prednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70:732–742PubMedCrossRefGoogle Scholar
  63. Hesselink D, Aarden L, Swaak A. Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus. Scand J Rheumatol 2003; 32:151–155PubMedCrossRefGoogle Scholar
  64. Ho C, Mok C, Lau C, Wong R. Late onset systemic lupus erythemato-sus in southern Chinese. Ann Rheum Dis 1998; 57:437–444PubMedCrossRefGoogle Scholar
  65. Ho A, Magder L, Barr S, Petri M. Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001a; 44:2342–2349CrossRefGoogle Scholar
  66. Ho A, Magder LS, Barr SG, Petri MA. A decrease in complement is associated with increased renal and hematologic flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001b; 44:2350–2357CrossRefGoogle Scholar
  67. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythemato-sus [letter]. Arthritis Rheum 1997; 40:1725PubMedCrossRefGoogle Scholar
  68. Huong DL, Papo T, Beaufuls H, Wechsler B. Renal involvement in systemic lupus erythematosus: A study of 180 patients from a single center. Medicine (Baltimore) 1999; 78:148CrossRefGoogle Scholar
  69. Iaboni A, Ibanez D, Gladman DD, Urowitz MB, Moldofsky H. Fatigue in systemic lupus erythematosus: Contributions of disordered sleep, sleepiness, and depression. J Rheumatol 2006; 33(12):2453–2457PubMedGoogle Scholar
  70. Iliopoulos A, Tsokos G. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996; 25:318–336PubMedCrossRefGoogle Scholar
  71. Ioannidis JP, Boki KA, Katsorida ME, et al Remission, relapse, and reremission of proliferative lupus nephritis treated with cyclophosph-amide. Kidney Int 2000; 57(1):258–264PubMedCrossRefGoogle Scholar
  72. Irving KS, Sen D, Tahir H, et al A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus ery-thematosus-a retrospective review of cases. Rheumatology (Oxford) 2007; 46(7):1171–1173CrossRefGoogle Scholar
  73. Isenberg D, Horsfall A. Systemic lupus erythematosus-adult onset. In: Maddison P, Isenberg D, Woo P, Glass D (eds) Oxford textbook of rheumatology. Oxford, Oxford University Press, 1998, pp. 1145–1180Google Scholar
  74. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythemato-sus who smoke are less responsive to antimalarial treatment. J Am AcadDermatol 2000; 42:983–987CrossRefGoogle Scholar
  75. Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, et al Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardio-lipin antibodies. Ann Rheum Dis 2004; 63(9):1075–1078PubMedCrossRefGoogle Scholar
  76. Jorizzo JL, Salisbury PL, Rogers RS 3rd, Goldsmith SM, Shar GG, Callen JP, Wise CM, Semble EL White WL. Oral lesions in systemic lupus erythematosus. Do ulcerative lesions represent a necrotizing vasculitis?. J Am Acad Dermatolo 1992; 27(3):389–394CrossRefGoogle Scholar
  77. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. DermatolTher 2007; 20:160–174Google Scholar
  78. Karpatkin S. Autoimmune thrombocytopaenic purpura. Semin Haematol 1985; 22:260–288Google Scholar
  79. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006; 15(6):366–370PubMedCrossRefGoogle Scholar
  80. Klippel JH, Karsh J, Stahl NI, et al A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979; 22:1321–1325PubMedCrossRefGoogle Scholar
  81. Koneru S, Shishov M, Ware A, Farhey Y, Mongey AB, Graham TB, et al Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum 2007; 57(6):1000–1006PubMedCrossRefGoogle Scholar
  82. Kroshinsky D, Stone JH, Bloch D, Stone JR. A 47-year-old woman with a nodular rash and numbness and pain in the legs. New England Journal of Medicine 2009; 360(7):711–20PubMedCrossRefGoogle Scholar
  83. Lee SS, Singh S, Magder LS, Petri M. Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythema-tosus. Lupus 2008; 17:114–23PubMedCrossRefGoogle Scholar
  84. Lin A. Chapter 36: Topical calcineurin inhibitors. In: Wolverton SE (ed) Comprehensive dermatologic drug therapy (2nd edn). Philadelphia, PA, Saunders Elsevier, 2007, pp. 671–689Google Scholar
  85. MacGowan J, Ellis S, Griffiths M, Isenberg D. Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology 2002; 41:981–987PubMedCrossRefGoogle Scholar
  86. Mackay IR et al Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet 1959; 1:65PubMedCrossRefGoogle Scholar
  87. Manoussakis M, Georgopoulou C, Zintzaras E, et al Sjogren's syndrome associated with systemic lupus erythematosus: Clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum 2004; 50:882–891PubMedCrossRefGoogle Scholar
  88. Manzi S, Meilahn E, Rairie J, et al Age-specific incidence rates of myo-cardial infarction and angina in women with systemic lupus erythe-matosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145:408–415PubMedCrossRefGoogle Scholar
  89. Marmor MF, Carr RE, Easterbrook M, et al Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. A report by the American Academy of Ophthalmology. Ophthalmology 2002; 109:1377–1382PubMedCrossRefGoogle Scholar
  90. McDonagh J, Isenberg D. Development of additional autoimmune disease in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 2000; 59:230–232PubMedCrossRefGoogle Scholar
  91. Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994; 37(8):1181–1188PubMedCrossRefGoogle Scholar
  92. Miot HA, Bartoli MLD, Haddad GR. Association between discoid lupus erythematosus and cigarette smoking. Dermatology 2005; 211:118–122PubMedCrossRefGoogle Scholar
  93. Modi GM, Maender JL, Coleman N, et al. Tineacorporis masquerading as subacutecutaneous lupus erythematosus. Dermatol Online J 2008; 15; 14(4):8PubMedGoogle Scholar
  94. Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative web-based database for lupus erythematosus associated skin lesions: 114 prospectively enrolled patients. Arch Dermatol 2009; 145(3):255–60PubMedCrossRefGoogle Scholar
  95. Mok C. Prognostic factors in lupus nephritis. Lupus 2005; 14:39–44PubMedCrossRefGoogle Scholar
  96. Neuwelt C, Lacks S, Kaye B, Ellman J, Borenstein D. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98:32–41PubMedCrossRefGoogle Scholar
  97. Ng K, Manson J, Rahman A, Isenberg D. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Care Res 2006; 55:900–904CrossRefGoogle Scholar
  98. Niiyama S, Katsuoka K, Happle R Hoffmann R. Multiple eruptive dermatofibromas: A review of the literature. Acta Derm Venereol 2002; 82(4):241–244PubMedCrossRefGoogle Scholar
  99. Nimmagadda SR, Spahn JD, Leung DY, Szefler SJ. Steroid-resistant asthma: Evaluation and management. [Review] [76 refs] [Journal Article. Research Support, Non-U.S. Gov't. Review] Ann Allergy Asthma Immunol 1996 Nov; 77(5):345–355; quiz 355–356PubMedCrossRefGoogle Scholar
  100. Noel V, Lortholary O, Casassus P, et al Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001; 60:1141–1144PubMedCrossRefGoogle Scholar
  101. Nossent H, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39:969–974PubMedCrossRefGoogle Scholar
  102. Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: Lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 2002; 29(3):482–486PubMedGoogle Scholar
  103. O'Neill S, Isenberg D. Immunizing patients with systemic lupus erythe-matosus: A review of effectiveness and safety. Lupus 2006; 15:778–783PubMedCrossRefGoogle Scholar
  104. Para MF, Finkelstein D, Becker S, et al Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. JAIDS 2000; 24(4):337–343PubMedGoogle Scholar
  105. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus ery-thematosus: Characteristics and long term outcome of this rare manifestation of the disease. Rheumatology 2008; 47:1498–1502PubMedCrossRefGoogle Scholar
  106. Perl A, Nagy G, Gergely P, et al Apoptosis and mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. Methods Mol Med 2004; 102:87–114PubMedGoogle Scholar
  107. Petri M. Musculoskeletal complications of systemic lupus erythemato-sus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 1995; 8:137–145PubMedCrossRefGoogle Scholar
  108. Petri M. Thrombosis and systemic lupus erythematosus: The Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25:191–193PubMedCrossRefGoogle Scholar
  109. Petri M. Infection in systemic lupus erythematosus. Rheumatic Dis Clin N Am 1998; 24:423–456CrossRefGoogle Scholar
  110. Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythemato-sus: A case-control study. J Rheumatol 1992; 19(2):265–269PubMedGoogle Scholar
  111. Petri M, Perez-Gutthann S, Longenecker J, Hochberg M. Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am J Med 1991a; 91:345–353CrossRefGoogle Scholar
  112. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence and clinical description of flare in systemic lupus erythematosus: A prospective cohort study. Arthritis Rheum 1991b; 34:937–944CrossRefGoogle Scholar
  113. Petri M, Kim M Y, Kalunian KC, et al Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2550–2558PubMedCrossRefGoogle Scholar
  114. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139(8):683–693PubMedCrossRefGoogle Scholar
  115. Pierangeli SS, Harris EN. In vivo models of thrombosis for the antiphos-pholipid syndrome. Lupus 1996; 5(5):451–455PubMedGoogle Scholar
  116. Porges AJ, Beattie SL, Ritchlin C, et al Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol 1992; 19(8):1191–1194PubMedGoogle Scholar
  117. Provost TT, Andres G, Maddison PJ Reichlin M. Lupus band test in untreated SLE patients: Correlation of immunoglobulin deposition in the skin of the extensor forearm with clinical renal disease and serological abnormalities. J Invest Dermatol 1980; 74(6):407–412PubMedCrossRefGoogle Scholar
  118. Pyne D, Isenberg D. Autoimmune thyroid diseases in systemic lupus erythematosus. Ann Rheum Dis 2002; 61:70–72PubMedCrossRefGoogle Scholar
  119. Ramos P, Mendez M, Ames P, Khamashta M, Hughes G. Pulse cyclo-phosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14:295–299PubMedGoogle Scholar
  120. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349(25):2399–2406PubMedCrossRefGoogle Scholar
  121. Ropes MW. Systemic lupus erythematosus. Cambridge, MA, Harvard University Press, 1976, p. 28Google Scholar
  122. Roy S, Tan K. Pyrexia and normal C-reactive protein (CRP) in patients with systemic lupus erythematosus: Always consider the possibility of infection in febrile patients with systemic lupus erythematosus regardless of CRP levels. Rheumatology 2001; 40:349–350PubMedCrossRefGoogle Scholar
  123. Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 1980; 69:187–194PubMedCrossRefGoogle Scholar
  124. Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001; 10(3):162–164PubMedCrossRefGoogle Scholar
  125. Scheinfeld N, Deleo VA. Photosensitivity in lupus erythematosus. Photodermatol Photoimmunol Photomed 2004; 20(5):272–279PubMedCrossRefGoogle Scholar
  126. Schmidt E, Brocker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008; 34(1):56–64PubMedCrossRefGoogle Scholar
  127. Sivaraj RR, Durrani OM, Denniston AK, et al Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46(12):1757–1762CrossRefGoogle Scholar
  128. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29(12):2531–2536PubMedGoogle Scholar
  129. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacutecuta-neous lupus erythematosus: A paradigm for bedside-to-bench patient-oriented translational clinical investigation Arch Dermatol Res 2009; 301(1):65–70PubMedCrossRefGoogle Scholar
  130. Spronk P, terBorg E, Kallenberg C. Patients with systemic lupus erythema-tosus and Jaccoud's arthropathy: A clinical subset with an increased C reactive protein response? Ann Rheum Dis 1992; 51:358–361PubMedCrossRefGoogle Scholar
  131. Stahl NI, Klippel JH, Decker JL. Fever in systemic lupus erythemato-sus. Am J Med 1979; 67:935–940PubMedCrossRefGoogle Scholar
  132. Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis carinii (jiroveci) prophylaxis? Insights from cases complicating autoimmune diseases. Arthritis Care & Research 2008; 59(7):1034–9CrossRefGoogle Scholar
  133. Takada K, Illei G, Boumpas D. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10:154–161PubMedCrossRefGoogle Scholar
  134. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004; 13(8):601–604PubMedCrossRefGoogle Scholar
  135. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfeld NF, et al The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271–1277PubMedCrossRefGoogle Scholar
  136. Taylor J, Skan J, Erb N, Carruthers D. Lupus patients with fatigue: Is there a link with fibromyalgia syndrome? Rheumatology 2000; 39:620–623PubMedCrossRefGoogle Scholar
  137. terBorg E, Horst G, Limburg P, vanRijswijk M, Kallenberg C. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: A prospective longitudinal study. J Rheumatol 1990; 17:1642–1648Google Scholar
  138. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7:80–85PubMedCrossRefGoogle Scholar
  139. Tsokos GC. Drugs, sun and T cells in lupus. Clin Exp Immunol 2004; 136(2):191–193PubMedCrossRefGoogle Scholar
  140. Turner-Stokes L, Cambridge G, Corcoran T, et al In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune disease. Ann Rheum Dis 1988; 47:532–535PubMedCrossRefGoogle Scholar
  141. Tzung TY, Liu YS Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: A randomized, double-blind, bilateral comparison study. Br J Dermatol 2007; 156(1):191–192PubMedCrossRefGoogle Scholar
  142. Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmunity reviews 2005; 4(4):219–223PubMedCrossRefGoogle Scholar
  143. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus ery-thematosus. Am J Med 1976; 60:221–225PubMedCrossRefGoogle Scholar
  144. Vassilakopoulos TP, Pangalis GA. Application of a prediction rule to select which patients presenting with lymphadenopathy should undergo a lymph node biopsy. Medicine (Baltimore) 2000; 79(5):338–347CrossRefGoogle Scholar
  145. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: A meta-analysis. Lupus 1997;6:467–473PubMedCrossRefGoogle Scholar
  146. Walz LeBlanc BAE, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus: Predictors of clinical flares. J Rheumatol 1994; 21:2239–2241PubMedGoogle Scholar
  147. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality. [Journal Article] Arthritis Rheum 1999 Apr; 42(4):780–789PubMedCrossRefGoogle Scholar
  148. Wassner SJ, Pennisi AJ, Malekzadeh MH, et al The adverse effect of anticonvulsant therapy on renal allograft survival. A preliminary report. J Pediatr 1976; 88:134–137PubMedCrossRefGoogle Scholar
  149. Wells JV, Webb J, Van Deventer M, et al In vivo anti-nuclear antibodies in epithelial biopsies in SLE and other connective tissue diseases. Clin Exp Immunol 1979; 38(3):424–435PubMedGoogle Scholar
  150. Werth VP, Sanchez M, White W, et al Incidence of alopecia areata in lupus erythematosus. Arch Derm 1992; 128:368–371PubMedCrossRefGoogle Scholar
  151. Wilson H, Hamilton M, Spyker D, et al Age influences the clinical and serologic expression of systemic lupus erythematosus. Arthritis Rheum 1981; 24:1230–1235PubMedCrossRefGoogle Scholar
  152. Zandman-Goddard G, Shoenfeld Y. SLE and infections. Clin Rev Allergy Immunol 2003; 25:29–40PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Michelle Petri
    • 1
  • Rachel Abuav
    • 2
  • Dimitrios Boumpas
    • 3
  • Fiona Goldblatt
    • 4
  • David Isenberg
    • 5
  • Grant J. Anhalt
    • 6
  • Victoria P. Werth
    • 7
  • R. John Looney
    • 8
  1. 1.Medicine, Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Johns Hopkins University, Department of DermatologyBaltimoreUSA
  3. 3.University of Crete. Department of MedicineGreece
  4. 4.Royal Adelaide Hospital North TerraceAdelaideAUSTRALIA
  5. 5.University College of London Center for Rheumatology ResearchLondonEngland
  6. 6.Johns Hopkins University, Department of DermatologyBaltimoreUSA
  7. 7.University of Pennsylvania DermatologyPhiladelphiaUSA
  8. 8.University of Rochester Division of RheumatologyNew YorkUSA

Personalised recommendations